Preview Mode Links will not work in preview mode
The AI in Business Podcast is for non-technical business leaders who need to find AI opportunities, align AI capabilities with strategy, and deliver ROI. Each week, Emerj Artificial Intelligence Research CEO Daniel Faggella interviews top AI executives from Fortune 500 firms and unicorn startups - to uncover trends, use-cases, and best practices for practical AI adoption. Subscribe to Emerj's weekly AI newsletter by downloading our "Beginning with AI" PDF guide here: https://emerj.com/aik

Nov 15, 2025

Today’s guest is Andrew Deutsch, CEO of the Fangled Group and Director of Operations at RR Donnelley. Fangled Group is a global marketing and sales consultancy specializing in data-driven strategies that accelerate market entry for small to medium-sized manufacturers. Andrew joins Emerj Editorial Director Matthew...


Nov 14, 2025

Today’s guest is Roanie Levy, Licensing and Legal Advisor, CCC. CCC provides collective copyright licensing services for corporate users of copyrighted materials. Roanie joins Emerj Editorial Director Matthew DeMello to break down how generative AI is changing copyright risk management for enterprises — from the...


Nov 13, 2025

Today’s guest is Trish Vassar, Vice President of Global Learning & Development, who brings over 20 years of experience in talent management, learning, and leadership development. She joins Emerj Editorial Director Matthew DeMello to explore how enterprise leaders can shift from traditional role-based planning to...


Nov 12, 2025

Today’s guest is Julian Tang, Chief Operations Officer for the Innovation Office at BlackRock. With extensive experience in financial technology and infrastructure, Julian specializes in integrating AI and data strategies to transform enterprise workflows. Julian joins Emerj Editorial Director Matthew DeMello to...


Nov 11, 2025

Today’s guest is Raul Monroig, People Organization Vice President for the Intercon Region at Bristol Myers Squibb. Bristol Myers Squibb manufactures prescription medicines across oncology, hematology, immunology, cardiovascular disease, and neuroscience. With a truly global footprint, the company’s research,...